Genetic testing improves treatment, survival for Black breast cancer patients

Tumor gene expression profiling was done using the MammaPrint and BluePrint tests from Agendia, which classify early-stage tumors as being at Ultra Low, Low, High 1, or High 2 risk for spreading throughout the body over the next 10 years. ​The results help to determine whether chemotherapy is necessary.